标签归档：grgdsp

GRGDSP TFA

发表于由

GRGDSP TFA; 纯度: ge;98.0%

GRGDSP (TFA) 是一种整联蛋白 (integrin) 抑制剂。

GRGDSP TFAamp;;

GRGDSP TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥880 In-stock
5 mg ￥1650 In-stock
10 mg ￥2850 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

GRGDSP TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptidomimetic Library
  • Peptide Library

生物活性

GRGDSP (TFA) is an integrin inhibitor.

IC50 Target

Integrin[1].
体外研究
(In Vitro)

It is demonstrated that transarterial infusion of GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro integrin-inhibitor which includes RGD-peptide). As a synthetic linear RGD peptide, GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro) can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis[1]. GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro) is used as a soluble integrin-blocking RGD-based peptide. GRGDSP is used widely together with other RGD peptides in integrin research. GRGDSP can be used to modify the surface of cardiovascular implants such as vascular grafts to promote endothelialization[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

701.61

Formula

C24H38F3N9O12
Sequence

Gly-Arg-Gly-Asp-Ser-Pro
Sequence Shortening

GRGDSP
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 125 mg/mL (178.16 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4253 mL 7.1265 mL 14.2529 mL
5 mM 0.2851 mL 1.4253 mL 2.8506 mL
10 mM 0.1425 mL 0.7126 mL 1.4253 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Qian J, et al. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol. 2016 Jun 7;22(21):5042-9.

    [2]. Patel S, et al. Regulation of endothelial cell function by GRGDSP peptide grafted on interpenetrating polymers. J Biomed Mater Res A. 2007 Nov;83(2):423-33.

GRGDSP

发表于由

GRGDSP;

GRGDSP 是一种合成的线性RGD肽，是一种整联蛋白 (integrin) 抑制剂。

GRGDSPamp;;

GRGDSP Chemical Structure

CAS No. : 91037-75-1

规格 价格 是否有货
5 mg ￥1600 询问价格 货期
10 mg ￥2900 询问价格 货期
25 mg ￥6400 询问价格 货期

* Please select Quantity before adding items.

GRGDSP 的其他形式现货产品:

GRGDSP TFA

生物活性

GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.

IC50 Target

Integrin[1]
体外研究
(In Vitro)

It is demonstrated that transarterial infusion of GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro integrin-inhibitor which includes RGD-peptide). As a synthetic linear RGD peptide, GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro) can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis[1]. GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro) is used as a soluble integrin-blocking RGD-based peptide. GRGDSP is used widely together with other RGD peptides in integrin research. GRGDSP can be used to modify the surface of cardiovascular implants such as vascular grafts to promote endothelialization[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

587.58

Formula

C22H37N9O10
CAS 号

91037-75-1
Sequence

Gly-Arg-Gly-Asp-Ser-Pro
Sequence Shortening

GRGDSP
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Qian J, et al. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol. 2016 Jun 7;22(21):5042-9.

    [2]. Patel S, et al. Regulation of endothelial cell function by GRGDSP peptide grafted on interpenetrating polymers. J Biomed Mater Res A. 2007 Nov;83(2):423-33.